Ionis Pharmaceuticals IONS Pre-Tax Income (Domestic)
Pre-Tax Income (Domestic) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's pre-tax income (domestic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's pre-tax income (domestic)?
- Ionis Pharmaceuticals (IONS) reported pre-tax income (domestic) of -$95.3M in Q4 2025.
- How has Ionis Pharmaceuticals's pre-tax income (domestic) changed year-over-year?
- Ionis Pharmaceuticals's pre-tax income (domestic) increased by 17.3% year-over-year, from -$115.18M to -$95.3M.
- What is the long-term trend for Ionis Pharmaceuticals's pre-tax income (domestic)?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's pre-tax income (domestic) has grown at a 6.7% compound annual growth rate (CAGR), from -$334.71M to -$381.18M.
- What does pre-tax income (domestic) mean?
- Pre-tax profit or loss generated solely from domestic business activities.
- How do you interpret pre-tax income (domestic)?
- An improvement indicates stronger domestic operational efficiency or market growth.
- How does pre-tax income (domestic) compare across companies?
- Standard geographic breakdown found in most multinational corporate tax disclosures.